Systemic Immune-Inflammation Index and Mortality in 1,084 Heart Failure Patients

1,084 heart failure patients were enrolled in a retrospective cohort study between January 2022 and June 2023. The dataset, authored by Junlan Zhang and last updated in April 2026, analyzes the association between the log-transformed systemic immune-inflammation index (LnSII) and all-cause and cardiovascular mortality, with follow-up until July 2025.

Use Cases

• Predicting all-cause mortality risk in heart failure patients based on systemic immune-inflammation index (SII) values.
• Conducting subgroup analysis to identify effect modifiers, such as smoking status, on the SII-mortality association.
• Performing mediation analysis to quantify the role of NT-proBNP and left ventricular ejection fraction (LVEF) in the observed association.
• Assessing the non-linear relationship between LnSII and mortality risk using restricted cubic spline models.

Strengths

• Contains data for 1,084 heart failure patients, providing a substantive cohort for analysis.
• Follow-up was conducted until July 2025, offering a defined observation period for mortality outcomes.
• Analysis includes fully adjusted hazard ratios, confidence intervals, and p-values for interaction, providing statistical rigor.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data table is unknown, which may limit suitability assessment.
• The study notes limited statistical power for cardiovascular mortality due to only 60 recorded events.

Provenance

Source

Junlan Zhang via figshare

Collection Method

Retrospective cohort study of patients hospitalized for heart failure.

Time Range

Patient enrollment from January 2022 to June 2023, with follow-up until July 2025.

Freshness

Last updated 2026-04-24 13:07:01; freshness should be verified.

Geography

Single-center study; geographic location is not specified.